Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro

Molecular Cancer Research

Volumn 1, Issue 11, 2003, Pages 826-835

  Adam, Paul J ^a   Berry, Joanne ^a   Loader, Julie A ^a   Tyson, Kerry L ^a   Craggs, Graham ^a   Smith, Paul ^a   De Belin, Jackie ^a   Steers, Graham ^b   Pezzella, Francesco ^b   Sachsenmeir, Kris F ^c   Stamps, Alasdair C ^a   Herath, Athula ^a   Sim, Edith ^e   O'Hare, Michael J ^d   Harris, Adrian L ^b   Terrett, Jonathan A ^a  

^a Oxford GlycoSciences   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c Automated Cell Inc   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE N ACETYLTRANSFERASE 1; CYTOTOXIC AGENT; ESTROGEN RECEPTOR; ETOPOSIDE; PROTEOME; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; COMPARATIVE TWO DIMENSIONAL PROTEOME ANALYSIS; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; EPITHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; STAINING;

ARYLAMINE N-ACETYLTRANSFERASE; BREAST; BREAST NEOPLASMS; CELL DIVISION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; ORGAN SPECIFICITY; PROTEOMICS; RNA, MESSENGER; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 12444303338     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Greenlee, R. T., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 2000. CA Cancer J. Clin., 50: 7-33, 2000
2. Brenner, T. L. and Adams, V. R. First MAb approved for treatment of metastatic breast cancer. J. Am. Pharm. Assoc. (Wash.), 39: 236-238, 1999.
3. DeRisi, J., Penland, L., Brown, P. O., Bittner, M. L., Meltzer, P. S., Ray, M., Chen, Y., Su, Y. A., and Trent, J. M. Use of a CDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet., 14: 457-460, 1996.
4. Brichory, F., Beer, D., Le Naour, F., Giordano, T., and Hanash, S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res., 61: 7908-7912, 2001.
5. Symmans, W. F., Ayers, M., Clark, E. A., Stec, J., Hess, K. R., Sneige, N., Buchholz, T. A., Krishnamurthy, S., Ibrahim, N. K., Buzdar, A. U., Theriault, R. L., Rosales, M. F., Thomas, E. S., Gwyn, K. M., Green, M. C., Syed, A. R., Hortobagyi, G. N., and Pusztai, L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer, 97: 2960-2971, 2003.
6. Adeyinka, A., Emberley, E., Niu, Y., Snell, L., Murphy, L. C., Sowter, H., Wykoff, C. C., Harris, A. L., and Watson, P. H. Analysis of gene expression in ductal carcinoma in situ of the breast. Clin. Cancer Res., 8: 3788-3795, 2002.
7. van't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., Schreiber, G. J., Kerkhoven, R. M., Roberts, C., Linsley, P. S., Bernards, R., and Friend, S. H. A gene-expression signature as a predictor of survival in breast cancer. Nature, 415: 530-536, 2002.
8. Zhu, G., Reynolds, L., Crnogorac-Jurcevic, T., Gillett, C. E., Dublin, E. A., Marshall, J. F., Barnes, D., D'Arrigo, C., Van Trappen, P. O., Lemoine, N. R., and Hart, I. R. Combination of microdissection and microarray analysis to identify gene expression changes between differentially located tumour cells in breast cancer. Oncogene, 22: 3742-3748, 2003.
9. Page, M. J., Amess, B., Townsend, R. R., Parekh, R., Herath, A., Brusten, L., Zvelebil, M. J., Stein, R. C., Waterfield, M. D., Davies, S. C., and O'Hare, M. J. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc. Natl. Acad. Sci. USA, 96: 12589-12594, 1999.
10. Weber, W. W. and Hein, D. W. N-acetylation pharmacogenetics. Pharmacol. Rev., 37: 25-79, 1985.
11. Bell, D. A., Badawi, A. F., Lang, N. P., Ilett, K. F., Kadlubar, F. F., and Hirvonen, A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res., 55: 5226-5229, 1995.
12. Badawi, A. F., Hirvonen, A., Bell, D. A., Lang, N. P., and Kadlubar, F. F. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res., 55: 5230-5237, 1995.
13. Stamps, A. C., Davies, S. C., Burman, J., and O'Hare, M. J. Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int. J. Cancer, 57: 865-874, 1994.
14. Harris, R. A., Eichholtz, T. J., Hiles, I. D., Page, M. J., and O'Hare, M. J. New model of ErbB-2 over-expression in human mammary luminal epithelial cells. Int. J. Cancer, 80: 477-484, 1999.
15. Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, O., Pergamenschikov, A., Williams, C., Zhu, S. X., Lonning, P. E., Borresen-Dale, A. L., Brown, P. O., and Botstein, D. Molecular portraits of human breast tumours. Nature, 406: 747-752, 2000.
16. Butcher, N. J., Arulpragasam, A., Pope, C., and Minchin, R. F. Identification of a minimal promoter sequence for the human arylamine N-acetyltransfemse acetyltransferase 1 gene that binds AP-1 and YY- I. Biochem. J., in press, 2003.
17. Boukouvala, S., Price, N., Plant, K. E., and Sim, E. Structure and transcriptional regulation of the Nat2 gene encoding for the drug metabolising enzyme arylamine N-acetyltransferase type 2 in mice. Biochem. J., in press, 2003.
18. Schnakenberg, E., Ehlers, C., Feyerabend, W., Werdin, R., Hubotter, R., Dreikom, K., and Schloot, W. Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients. Clin. Genet., 53: 396-402, 1998.
19. Roberts-Thomson, I. C., Ryan, P., Khoo, K. K., Hart, W. J., McMichael, A. J., and Butler, R. N. Diet, acetylator phenotype, and risk of colorectal neoplasia. Lancet, 347: 1372- 1374, 1996.
20. Abdel-Rahman, S. Z., El-Zein, R. A., Zwischenberger, J. B., and Au, W. W. Association of the NAT1*10 genotype with increased chromosome aberrations and higher lung cancer risk in cigarette smokers. Mutat. Res., 398: 43-54, 1998.
21. Stanley, L. A., Coroneos, E., Cuff, R., Hickman, D., Ward, A., and Sim, E. Immunochemical detection of arylamine N-acetyltransferase in normal and neoplastic bladder. J. Histochem. Cytochem., 44: 1059-1067, 1996.
22. Williams, J. A., Stone, E. M., Fakis, G., Johnson, N., Cordell, J. A., Meinl, W., Glatt, H., Sim, E., and Phillips, D. H. N-acetyltransferases, sulfotransferases and heterocyclic amine activation in the breast. Pharmacogenetics, 11: 373-388, 2001.
23. Pathology Reporting in Breast Cancer Screening (2nd Edition). NHSBSP ISBN 1 87 1997 22 4.
24. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. Real time quantitative PCR. Genome Res., 6: 986-994, 1996.
25. Morrison, T. B., Weis, J. J., and Wittwer, C. T. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques, 24: 954-958, 1998.